Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

J Clin Oncol. 2012 Jun 20;30(18):2179-82. doi: 10.1200/JCO.2012.42.0695. Epub 2012 May 21.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracyclines / administration & dosage*
  • Anthracyclines / adverse effects*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Chemotherapy, Adjuvant
  • Heart Failure / chemically induced
  • Humans
  • Molecular Targeted Therapy
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab

Substances

  • Anthracyclines
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab